Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Agios Pharmaceuticals
Pharma
In a first, FDA approves Servier's Voranigo in low-grade gliomas
Servier's Voranigo, or vorasidenib, is now the first systemic therapy for low-grade IDH-mutant brain cancer.
Angus Liu
Aug 6, 2024 5:25pm
Agios' Pyrukynd misses the mark in first pediatric study
Aug 1, 2024 1:08pm
Agios charts broad path for oral thalassemia med after trial win
Jan 3, 2024 10:49am
Alnylam, Intra-Cellular among RBC's top picks for M&A
Apr 19, 2023 3:20pm
After pivot, Agios names Alexion vet Goff its next CEO
Jul 12, 2022 4:40pm
Agios' first-in-class PK activator Pyrukynd scores FDA nod
Feb 17, 2022 4:50pm
